Key Technologies for Progressing Discovery of Microbiome-Based Medicines
2021
Remy B. Young | Remy B. Young | Vanessa R. Marcelino | Vanessa R. Marcelino | Michelle Chonwerawong | Michelle Chonwerawong | Emily L. Gulliver | Emily L. Gulliver | Emily L. Gulliver | Samuel C. Forster | Samuel C. Forster | Samuel C. Forster
A growing number of experimental and computational approaches are illuminating the “microbial dark matter” and uncovering the integral role of commensal microbes in human health. Through this work, it is now clear that the human microbiome presents great potential as a therapeutic target for a plethora of diseases, including inflammatory bowel disease, diabetes and obesity. The development of more efficacious and targeted treatments relies on identification of causal links between the microbiome and disease; with future progress dependent on effective links between state-of-the-art sequencing approaches, computational analyses and experimental assays. We argue determining causation is essential, which can be attained by generating hypotheses using multi-omic functional analyses and validating these hypotheses in complex, biologically relevant experimental models. In this review we discuss existing analysis and validation methods, and propose best-practice approaches required to enable the next phase of microbiome research.
Mostrar más [+] Menos [-]Palabras clave de AGROVOC
Información bibliográfica
Este registro bibliográfico ha sido proporcionado por Directory of Open Access Journals
